State-by-State Telehealth Advertising Rules in 2026

State-by-state telehealth advertising rules are an underappreciated compliance layer for brands running national campaigns. Federal FDA and FTC requirements apply everywhere — but state laws add additional obligations that vary substantially by geography. A national advertising campaign that complies fully with federal law may still violate state-specific advertising disclosure requirements, physician-patient relationship rules for telehealth, or right-of-publicity protections. For brands running seven-figure annual ad budgets across the country, failing to account for state-level requirements is a meaningful risk.

This guide covers the states with the most material telehealth advertising rules in 2026, focusing on laws that have changed recently or that create compliance obligations that differ significantly from the federal baseline. It is not a comprehensive legal analysis — state law changes frequently and telehealth brands should work with counsel in each state where they have significant patient volume. But it provides a practical starting point for understanding where state-level rules are most likely to affect your advertising program.

New York — The Most Active State for Telehealth Advertising Law in 2026

New York is the state with the most significant new telehealth advertising regulation in 2026. The New York Synthetic Performer Law, effective June 9, 2026, creates a new state right of publicity for digital replicas of real people in commercial advertising. Fines of $1,000 per violation and $5,000 per knowing violation apply to any commercial use of a digital replica without written consent — regardless of where the advertiser is headquartered. Any telehealth brand running national paid social campaigns that reach New York users is subject to this law. See our detailed analysis of the New York Synthetic Performer Law for the full compliance requirements.

New York also has state-specific rules governing telehealth advertising for licensed healthcare professionals. The New York State Office of the Professions has issued guidance on advertising standards for licensed professions — including medicine, nursing, and pharmacy — that are stricter than FTC requirements in some respects. New York's advertising rules for licensed professionals prohibit certain types of testimonials and require specific disclosure language for healthcare advertising that goes beyond the federal baseline. Telehealth brands whose advertising features or implies the endorsement of New York-licensed providers should review these rules with counsel.

California — Broad Consumer Protection Framework

California's consumer protection laws — particularly the California Consumer Privacy Act (CCPA) and the California Unfair Competition Law (UCL) — create a broad framework that affects telehealth advertising in ways that other states do not. The UCL allows private plaintiffs and the Attorney General to sue for any "unfair" or "deceptive" business practice, which in practice means that California has a state-level enforcement mechanism for advertising claims that is parallel to the FTC's federal enforcement authority and can result in state-level legal action independent of any federal enforcement.

California also has specific rules for healthcare advertising through the Medical Board of California's advertising standards, which apply to advertising by or on behalf of California-licensed physicians. Advertising that implies physician endorsement of a telehealth service, or that uses physician credentials in ways the Medical Board has restricted, creates state-level exposure for both the physician and the telehealth brand. California's right-of-publicity statute (Civil Code § 3344) also restricts commercial use of a person's likeness without consent — providing a similar protection to the New York law for California residents, though with different penalty structures.

Texas — Compounding and Pharmacy Advertising

Texas has specific regulations through the Texas State Board of Pharmacy that govern how compounding pharmacies and telehealth services associated with them can advertise. Texas pharmacies are prohibited from advertising in ways that are false, misleading, or deceptive, with specific provisions about advertising claims for compounded medications. For telehealth brands that work with Texas-based compounding pharmacies or that advertise compounded medication access to Texas patients, the TSBP advertising rules create compliance obligations that go beyond the FDA framework.

Texas also has active enforcement of its Deceptive Trade Practices-Consumer Protection Act (DTPA), which provides consumers and the state Attorney General with claims against deceptive business practices including deceptive health advertising. The DTPA has been used in Texas to pursue healthcare companies making misleading advertising claims in cases that would also support FTC enforcement. Telehealth brands with significant Texas patient volume should treat DTPA compliance as a parallel obligation to FTC compliance.

Florida — Telehealth Prescribing and Advertising Rules

Florida has been an active state for telehealth regulation, with the Florida Board of Medicine having specific rules about telehealth prescribing standards that affect how services can be advertised. Florida prohibits telehealth providers from prescribing certain controlled substances via telehealth without in-person evaluation, and advertising that implies Florida patients can receive prescriptions for those substances via telehealth without meeting those requirements creates both state medical board exposure and potential consumer deception claims.

Florida's consumer protection laws — the Florida Deceptive and Unfair Trade Practices Act (FDUTPA) — also provide state-level enforcement for health advertising violations. Florida has a track record of active enforcement of FDUTPA in the health and wellness advertising space. Telehealth brands advertising weight loss programs, ED treatment, and hormone therapy to Florida consumers should review FDUTPA compliance as part of their state-level compliance program.

Illinois and the Biometric Information Privacy Act Angle

Illinois's Biometric Information Privacy Act (BIPA) has implications for telehealth advertising that are not immediately obvious. BIPA restricts the commercial collection and use of biometric identifiers — including facial scans and retinal scans. For telehealth brands using AI-powered tools in their advertising workflow that scan or use facial imagery data, BIPA may apply. This is particularly relevant for brands using AI tools that analyze patient photos (such as for hair loss or skin condition assessment) in ways that involve Illinois-based users.

Illinois also has a right-of-publicity statute (Illinois Right of Publicity Act) that restricts commercial use of a person's identity — name, voice, photograph — without consent. The Illinois statute applies to digital uses and provides a state-law basis for claims against unauthorized commercial use of a person's likeness in advertising, parallel to the New York law for Illinois-based individuals. Telehealth brands using real patient imagery in advertising to Illinois audiences should have written consent documentation that meets the Illinois statute's requirements.

States With Active Compounding Regulation

Several states have enacted specific regulations for compounding pharmacy advertising beyond the FDA's framework. Ohio, Michigan, and North Carolina have state pharmacy board rules that impose additional restrictions on how compounded medication services can be advertised to state residents. These rules typically focus on avoiding misleading claims about the safety or efficacy of compounded products and requiring specific disclosures about compounded medications' non-FDA-approved status. Brands advertising compounded GLP-1, compounded ED medications, or compounded hair loss treatments in these states should review state pharmacy board advertising guidance.

The practical approach for most telehealth brands is not to research every state's specific compounding advertising rules individually — that project would require significant legal resources and would become outdated as state rules evolve. Instead, building advertising that meets the most stringent applicable state standard creates a de facto national standard that covers most state variations. The national standard approach requires identifying which states have the most stringent requirements — currently New York, California, Texas, and Florida — and designing your advertising program to meet those requirements, with confidence that it will meet the less stringent requirements in most other states. See our overview of state telehealth advertising rules for the baseline state-level framework.

Building a Multi-State Compliance Approach

A practical multi-state compliance approach for telehealth brands running national advertising has two components. First, a tracking system that monitors state-level legislative and regulatory developments in the states where you have significant patient volume — so you learn about material state-law changes before your advertising is affected by them rather than after. Second, a tiered advertising standard that applies the strictest applicable state requirements to all advertising, rather than trying to create state-specific ad variants for each jurisdiction.

The tiered standard approach works for most telehealth brands because the states with the most stringent advertising requirements — New York, California, Texas, Florida, Illinois — collectively represent a large enough share of the US telehealth patient population that meeting their requirements is a practical necessity regardless. Building the compliance program around those states and applying it nationally creates consistency and simplicity while meeting the highest state-level standards. See our guide to building a live compliance tracker for how to systematize the monitoring component of this approach.